Lundbeck wins patent case against six generic medicine producers

A legal dispute over the patent rights for depression treatment Trintellix has been resolved in favor of Lundbeck and its partner Takeda, as a US judge has ruled to uphold patent protection on the drug's active ingredient.

Photo: Jens Dresling

Lundbeck has managed to stave off generic medicine producers – for now. The company and its partner, Takeda, have won a legal battle in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs